Form 4: Fennec Pharmaceuticals Director Sells Shares Under 10b5-1 Plan

A Fennec Pharmaceuticals director, Rosty Raykov, sold 796 common shares at $6.04 per share on December 5, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Rosty Raykov, a director at Fennec Pharmaceuticals, sold 796 common shares of the company on December 5, 2024.
• The shares were sold at a price of $6.04 each.
• This transaction was executed under a pre-existing 10b5-1 trading plan established on December 14, 2023.
• Following the sale, Mr. Raykov directly owns 66,432 common shares of Fennec Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider share sale under a pre-arranged plan, which is neither positive nor negative for the company's prospects.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 plan indicates that the sale was pre-planned and not based on any recent non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of trading on non-public information.
• The sale of 796 shares is a relatively small transaction compared to the total number of shares outstanding for Fennec Pharmaceuticals, and is unlikely to have a significant impact on the stock price.
• Other pharmaceutical companies often see similar Form 4 filings from their directors and officers.

Stakeholder Impact

• The share sale is unlikely to have a significant impact on shareholders due to the small volume of shares sold.

Key Dates

Keywords

Fennec Pharmaceuticals, insider trading, Form 4, 10b5-1 plan, share sale, Rosty Raykov, director